{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "SERD_ZB-716",
  "nciThesaurus": {
    "casRegistry": "1853279-29-4",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally bioavailable selective estrogen receptor degrader/downregulator (SERD) and a structural analog of fulvestrant, with potential antineoplastic activity. Upon oral administration, SERD ZB-716 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.",
    "fdaUniiCode": "E35ZN95LMT",
    "identifier": "C179265",
    "preferredName": "SERD ZB-716",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C2116"
    ],
    "synonyms": [
      "Borestrant",
      "SERD ZB-716",
      "Selective Estrogen Receptor Alpha Degrader ZB716",
      "Selective Estrogen Receptor Degrader ZB716",
      "ZB 716",
      "ZB-716",
      "ZB716"
    ]
  }
}